Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, 2835, 2023)

被引：0

作者：

Kirkwood, John M. ^{[1
]}

Del Vecchio, Michele ^{[2
]}

Weber, Jeffrey ^{[3
]}

Hoeller, Christoph ^{[4
]}

Grob, Jean-Jacques ^{[5
]}

Mohr, Peter ^{[6
]}

Loquai, Carmen ^{[7
]}

Dutriaux, Caroline ^{[8
]}

Chiarion-Sileni, Vanna ^{[9
]}

Mackiewicz, Jacek ^{[10
]}

Rutkowski, Piotr ^{[11
]}

Arenberger, Petr ^{[12
]}

Quereux, Gaelle ^{[13
]}

Meniawy, Tarek M. ^{[14
]}

Ascierto, Paolo A. ^{[15
]}

Menzies, Alexander M. ^{[16
]}

Durani, Piyush ^{[17
]}

Lobo, Maurice ^{[17
]}

Campigotto, Federico ^{[17
]}

Gastman, Brian ^{[18
]}

Long, Georgina V. ^{[16
]}

机构：

[1] UPMC Hillman Canc Ctr, Hillman Canc Ctr, Pittsburgh, PA 15232 USA

[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] NYU, Langone Med Ctr, New York, NY USA

[4] Med Univ Wien, Vienna, Austria

[5] Hop La Timone, Marseille, France

[6] Elbe Klinikum Buxtehude, Buxtehude, Germany

[7] Univ Med Ctr Mainz, Mainz, Germany

[8] Hop St Andre, Bordeaux, France

[9] Ist Oncol Veneto, IOV IRCCS, Padua, Italy

[10] Poznan Univ Med Sci, Inst Oncol, Poznan, Poland

[11] Mar Sklodowska Curie Natl Res Inst Oncol, Gynecol Oncol, Warsaw, Poland

[12] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Cardiol, Prague, Czech Republic

[13] Nantes Univ Hosp, Nantes, France

[14] Univ Western Australia, Sir Charles Gairdner Hosp, Perth, WA, Australia

[15] Ist Nazl Tumori IRCCS Fondaz G Pascale, Naples, Italy

[16] Univ Sydney, Royal North Shore & Mater Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Cleveland Clin, Cleveland Hts, OH USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1038/s41591-023-02775-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：906 / 906

页数：1

共 50 条

[1] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
Kirkwood, John
Del Vecchio, Michele
Weber, Jeffrey
Hoeller, Christoph
Grob, Jean-Jacques
Mohr, Peter
Loquai, Carmen
Dutriaux, Caroline
Chiarion-Sileni, Vanna
Mackiewicz, Jacek
Rutkowski, Piotr
Arenberger, Petr
Quereux, Gaelle
Meniawy, Tarek M.
Ascierto, Paolo A.
Menzies, Alexander M.
Durani, Piyush
Lobo, Maurice
Campigotto, Federico
Gastman, Brian
Long, Georgina V.
NATURE MEDICINE, 2023, 29 (11) : 2835 - 2843
[2] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M. Kirkwood
Michele Del Vecchio
Jeffrey Weber
Christoph Hoeller
Jean-Jacques Grob
Peter Mohr
Carmen Loquai
Caroline Dutriaux
Vanna Chiarion-Sileni
Jacek Mackiewicz
Piotr Rutkowski
Petr Arenberger
Gaelle Quereux
Tarek M. Meniawy
Paolo A. Ascierto
Alexander M. Menzies
Piyush Durani
Maurice Lobo
Federico Campigotto
Brian Gastman
Georgina V. Long
Nature Medicine, 2023, 29 : 2835 - 2843
[3] Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M. Kirkwood
Michele Del Vecchio
Jeffrey Weber
Christoph Hoeller
Jean-Jacques Grob
Peter Mohr
Carmen Loquai
Caroline Dutriaux
Vanna Chiarion-Sileni
Jacek Mackiewicz
Piotr Rutkowski
Petr Arenberger
Gaelle Quereux
Tarek M. Meniawy
Paolo A. Ascierto
Alexander M. Menzies
Piyush Durani
Maurice Lobo
Federico Campigotto
Brian Gastman
Georgina V. Long
Nature Medicine, 2024, 30 : 607 - 607
[4] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (16 OCT, 10.1038/s41591-023-02583-2, 2023 )
Kirkwood, John M.
Del Vecchio, Michele
Weber, Jeffrey
Hoeller, Christoph
Grob, Jean-Jacques
Mohr, Peter
Loquai, Carmen
Dutriaux, Caroline
Chiarion-Sileni, Vanna
Mackiewicz, Jacek
Rutkowski, Piotr
Arenberger, Petr
Quereux, Gaelle
Meniawy, Tarek M.
Ascierto, Paolo A.
Menzies, Alexander M.
Durani, Piyush
Lobo, Maurice
Campigotto, Federico
Gastman, Brian
Long, Georgina V.
NATURE MEDICINE, 2023, 30 (2) : 607 - 607
[5] Adjuvant Therapy With Nivolumab Versus Placebo in Patients With Resected Stage IIB/C Melanoma (Checkmate 76K)
Gastman, Brian
Long, Georgina V.
Kirkwood, John M.
Hoeller, Christoph
Weber, Jeffrey
Grob, Jean-Jacques
Mohr, Peter
Grabbe, Stephan
Dutriaux, Caroline
Chiarion-Sileni, Vanna
Mackiewicz, Jacek
Rutkowski, Piotr
Arenberger, Petr
Quereux, Gaelle
Meniawy, Tarek
Ascierto, Paolo A.
van Akkooi, Alexander
Durani, Piyush
Campigotto, Federico
Del Vecchio, Michele
ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S35 - S36
[6] Adjuvant nivolumab (NIVO) v placebo (PBO) in stage IIB/C melanoma: Update from CheckMate 76K
Kirkwood, J. M.
Weber, J.
Hoeller, C.
Grob, J.
Mohr, P.
Grabbe, S.
Dutriax, C.
Chiarion-Sileni, V.
Mackiewicz, J.
Rutkowski, P.
Arenberger, P.
Meniawy, T.
Dalle, S.
Mandala, M.
van Akkooi, A.
Nassar, A.
Campigotto, F.
Long, G. V.
Del Vecchio, M.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S48 - S48
[7] Adjuvant Nivolumab (NIVO) Versus Ipilimumab (IPI) in Resected Stage III/IV Melanoma: 3-Year Efficacy and Biomarker Results From the Phase 3 Checkmate 238 Trial
Weber, J.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Butler, M.
Maio, M.
Vetto, J.
Tang, H.
Saci, A.
de Pril, V.
Lobo, M.
Larkin, J.
Ascierto, P. A.
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S144 - S144
[8] Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
Kirkwood, John M.
Del Vecchio, Michele
Weber, Jeffrey
Hoeller, Christoph
Grob, Jean-Jacques
Mohr, Peter
Loquai, Carmen
Dutriaux, Caroline
Chiarion-Sileni, Vanna
Mackiewicz, Jacek
Rutkowski, Piotr
Arenberger, Petr
Quereux, Gaelle
Meniawy, Tarek M.
Ascierto, Paolo A.
Menzies, Alexander M.
Durani, Piyush
Lobo, Maurice
Campigotto, Federico
Gastman, Brian
Long, Georgina, V
FUTURE ONCOLOGY, 2024, 20 (15) : 959 - 968
[9] Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Weber, J. S.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J. J.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Butler, M. O.
Maio, M.
Middleton, M. R.
Tang, T.
Saci, A.
De Pril, V.
Lobo, M.
Larkin, J. M. G.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2019, 30 : 533 - +
[10] Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Ascierto, Paolo A.
Del Vecchio, Michele
Mandala, Mario
Gogas, Helen
Arance, Ana M.
Dalle, Stephane
Cowey, C. Lance
Schenker, Michael
Grob, Jean-Jacques
Chiarion-Sileni, Vanna
Marquez-Rodas, Ivan
Butler, Marcus O.
Maio, Michele
Middleton, Mark R.
de la Cruz-Merino, Luis
Arenberger, Petr
Atkinson, Victoria
Hill, Andrew
Fecher, Leslie A.
Millward, Michael
Khushalani, Nikhil, I
Queirolo, Paola
Lobo, Maurice
de Pril, Veerle
Loffredo, John
Larkin, James
Weber, Jeffrey
LANCET ONCOLOGY, 2020, 21 (11): : 1465 - 1477

← 1 2 3 4 5 →